Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADACEL® Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

NCT00282295
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Boostrix®, Menactra™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
24
States / cities
Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 4, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

NCT00258882
View directory record Official record
Conditions
Pertussis
Interventions
Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
327,293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 4, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Database Surveillance Safety Study of PENTACEL® Vaccine

NCT00804284
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae
Interventions
DTaP-IPV/Hib, Other DTap Vaccines
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Weeks to 24 Months · Male only
Enrollment
62,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older

NCT00457249
View directory record Official record
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Chandler, Arizona • Phoenix, Arizona • Cypress, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

NCT00319553
View directory record Official record
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
11 Years to 18 Years
Enrollment
647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

NCT02052596
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

NCT00835237
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions
Boostrix®, Decavac™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
1,332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
24
States / cities
Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

NCT02587520
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years and older
Enrollment
1,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

NCT00802867
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis, Polio, Haemophilus Infection
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
19
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

NCT00263692
View directory record Official record
Conditions
Diphtheria, Acellular Pertussis, Tetanus
Interventions
Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

NCT00258895
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis
Interventions
DAPTACEL®: DTaP
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
649 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
22
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 4, 2026, 9:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

NCT00297856
View directory record Official record
Conditions
Diphtheria, Tetanus, Acellular Pertussis
Interventions
Boostrix®, Td (Tetanus diphtheria) vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 18 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Results available

Tdap Vaccine in Post-Partum Women

NCT01711645
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

NCT01439165
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine, Tetanus and Diphtheria Toxoids Adsorbed For Adult Use
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
31
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

NCT02543918
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab, Boostrix®, Pneumovax®23
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 4, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047
View directory record Official record
Conditions
Diphtheria, Polio, Pertussis
Interventions
DAPTACEL®. (DTaP), IPOL®., and ActHIB®., Pentacel®: DTaP-IPV/Hib combined, DTaP-IPV and ActHIB®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
36
States / cities
Tuscaloosa, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 4, 2026, 9:43 PM EDT